



Physician Quality Reporting Guide

2017

Contents

Chapter 1: Introduction 1

Information, Tips, and Tools for Implementation	1
Medicare Quality Initiatives	2
Implementing the Process	3

Chapter 2: An Overview of PQRS and Other Quality Initiatives 7

Institute of Medicine	7
Identifying and Prioritizing Quality Measures	7
National Committee for Quality Assurance	7
Pay for Performance	8
Development of Quality Measures	9
Physician Quality Reporting System	10
Reporting Options	12
Claims-based Reporting	12
Registry Reporting	13
Electronic Health Record	14
Medicare EHR Incentive Program 2015	14
Stage 1	15
Stage 2	18
Documentation for Non-Percentage-Based Objectives	20
Electronic Prescribing Incentive Program	21
Group Practice Reporting Option	21
Physician Feedback/Value-based Payment Modifier Program	22
Qualified Clinical Data Registry Reporting	22
CMS-Certified Survey Vendor	22
Accountable Care Organizations	23

Chapter 3: Selecting and Reporting Quality

Measures 25

Reporting Options	25
Group Practice/Accountable Care Organization Reporting Option	31
Electronic Health Records	35

Chapter 4: Individual Measure Specifications 39

Overview of Quality Measure Specifications 39

Measures Category: Acquired Infections, Other 40

Measure 76. Prevention of Central Venous Catheter (CVC)-Related Bloodstream Infections	40
--	----

Measures Category: Adult and Pediatric Kidney Disease 41

Measure 81. Adult Kidney Disease: Hemodialysis Adequacy: Solute	41
Measure 82. Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	42
Measure 121. Adult Kidney Disease: Laboratory Testing (Lipid Profile)	42
Measure 122. Adult Kidney Disease: Blood Pressure Management	43

Measure 172. Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	43
Measure 327. Pediatric Kidney Disease: Adequacy of Volume Management	44
Measure 328. Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL	44
Measure 329. Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis	45
Measure 330. Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days	45

Measures Category: Adult Primary Rhegmatogenous Retinal Detachment Surgery 47

Measure 384. Adult Primary Rhegmatogenous Retinal Detachment Repair Success Rate	47
Measure 385. Adult Primary Rhegmatogenous Retinal Detachment Surgery Success Rate	47

Measures Category: Age-Related Macular Degeneration 49

Measure 14. Age-Related Macular Degeneration (AMD): Dilated Macular Examination	49
Measure 140. Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	50

Measures Category: Aneurysm 51

Measure 258. Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	51
Measure 259. Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	52
Measure 347. Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital	52

Measures Category: Arthritis 53

Measure 109. Osteoarthritis (OA): Function and Pain Assessment	53
Measure 178. Rheumatoid Arthritis (RA): Functional Status Assessment	53

Measures Category: Asthma/URI/Pharyngitis

Measures 55

Measure 53. Asthma: Pharmacologic Therapy for Persistent Asthma — Ambulatory Care Setting	55
---	----

Measure 65. Appropriate Treatment for Children with Upper Respiratory Infection (URI)	56
Measure 66. Appropriate Testing for Children with Pharyngitis	56
Measure 116. Avoidance of Antibiotic Treatment of/in Adults with Acute Bronchitis: Avoidance of Inappropriate Use	57
Measure 398. Optimal Asthma Control	58
Measures Category: Atrial Fibrillation and Flutter	60
Measure 326. Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy	60
Measure 392. HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation	61
Measures Category: Bypass Graft	62
Measure 43. Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	62
Measure 44. Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	63
Measure 164. Coronary Artery Bypass Graft (CABG): Prolonged Intubation	63
Measure 165. Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	64
Measure 166. Coronary Artery Bypass Graft (CABG): Stroke	64
Measure 167. Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	65
Measure 168. Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	65
Measure 257. Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	66
Measures Category: Carotid Artery Procedures	67
Measure 344. Rate of Carotid Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Postoperative Day #2)	67
Measure 345. Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS)	67
Measures Category: Cataracts	69
Measure 191. Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery	69
Measure 192. Cataracts: Complications Within 30 days Following Cataract Surgery Requiring Additional Surgical Procedures	71
Measure 303. Cataracts: Improvement in the Patient's Visual Function within 90 Days Following Cataract Surgery	72
Measure 304. Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	73
Measure 388. Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy)	74
Measure 389. Cataract Surgery: Difference Between Planned and Final Refraction	74
Measures Category: Chronic Obstructive Pulmonary Disease	76
Measure 51. Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	76
Measure 52. Chronic Obstructive Pulmonary Disease (COPD): Inhaled Bronchodilator Therapy	76
Measures Category: Coronary Artery Disease	78
Measure 6. Coronary Artery Disease (CAD): Antiplatelet Therapy	78
Measure 7. Coronary Artery Disease (CAD): Beta-blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	79
Measure 118. Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)	80
Measure 242. Coronary Artery Disease (CAD) Symptom Management	81
Measures Category: Depression/Major Depressive Disorder	83
Measure 134. Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan	83
Measure 325. Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions	84
Measures Category: Diabetes	85
Measure 1. Diabetes: Hemoglobin A1c Poor Control	85
Measure 117. Diabetes: Eye Exam	85
Measure 119. Diabetes: Medical Attention for Nephropathy	86
Measure 126. Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	87
Measure 127. Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	88
Measure 163. Diabetes: Foot Exam	88
Measures Category: Diabetic Retinopathy	90
Measure 19. Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	90
Measures Category: Elder Care	91
Measure 47. Care Plan	91
Measure 181. Elder Maltreatment Screen and Follow-up Plan	91
Measure 386. Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences	92
Measures Category: Emergency Medicine	94
Measure 54. Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	94

Measures Category: Endarterectomy	95	Measure 69. Hematology: Multiple Myeloma: T reatment With Bisphosphonates	116
Measure 260. Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)	95	Measure 70. Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	116
Measures Category: Endoscopy & Polyp Surveillance	96	Measure 71. Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	117
Measure 185. Colonoscopy Interval for Patients with a History of Adenomatous Polyps— Avoidance of Inappropriate Use	96	Measure 72. Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	118
Measures Category: Epilepsy	97	Measure 99. Breast Cancer Resection Pathology Reporting: Pt Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	119
Measure 268. Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	97	Measure 100. Colorectal Cancer Resection Pathology: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	119
Measures Category: Fall	98	Measure 102. Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	120
Measure 154. Falls: Risk Assessment	98	Measure 104. Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	120
Measure 155. Falls: Plan of Care	99	Measure 143. Oncology: Medical and Radiation— Pain Intensity Quantified	121
Measures Category: Functional Deficits	100	Measure 144. Oncology: Medical and Radiation— Plan of Care for Pain	121
Measure 217. Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	100	Measure 156. Oncology: Radiation Dose Limits to Normal Tissues	122
Measure 218. Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	101	Measure 194. Oncology: Cancer Stage Documented	122
Measure 219. Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	103	Measure 263. Preoperative Diagnosis of Breast Cancer	123
Measure 220. Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	104	Measure 264. Sentinel Lymph Node Biopsy for Invasive Breast Cancer	124
Measure 221. Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	106	Measure 395. Lung Cancer Reporting (Biopsy/Cytology Specimens)	124
Measure 222. Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Hand or Wrist Impairments	107	Measure 396. Lung Cancer Reporting (Resection Specimens)	125
Measure 223. Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	108	Measures Category: Hepatitis C	126
Measures Category: Heart Failure	111	Measure 387. Annual Hepatitis C Virus (HCV) Screening for Patient who are Active Injection Drug Users	126
Measure 5. Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	111	Measure 390. Discussion and Shared Decision Making Surrounding Treatment Options	126
Measure 8. Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	112	Measure 400. Hepatitis C: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk	127
Measures Category: Hematology and Oncology Measures	114	Measure 401. Screening for Hepatocellular Carcinoma (HCC) in Patients with Hepatitis Cirrhosis	128
Measure 67. Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	115	Measures Category: Human Immunodeficiency Virus/Acquired Immune Deficiency	129
Measure 68. Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	115	Measure 205. HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis	129
		Measures Category: Hypertension	130
		Measure 236. Controlling High Blood Pressure	130

Measures Category: Ischemic Vascular**Disease (IVD) 131**

- Measure 204. Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic 131
- Measure 349. Optimal Vascular Care Composite 131

Measures Category: Medication Reconciliation 133

- Measure 46. Medication Reconciliation 133
- Measure 130. Documentation of Current Medications in the Medical Record 133

Measures Category: Melanoma 135

- Measure 137. Melanoma: Continuity of Care—Recall System 135
- Measure 138. Melanoma: Coordination of Care 135
- Measure 224. Melanoma: Overutilization of Imaging Studies in Melanoma 136
- Measure 397. Melanoma Reporting 137

Measure Category: Mental Health 138

- Measure 391. Follow-up After Hospitalization for Mental Illness (FUH) 138

Measures Category: Ocular Disorders Other Than**Cataract 139**

- Measure 12. Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation 139
- Measure 141. Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care 139

Measures Category: Osteoporosis 141

- Measure 24. Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older 141
- Measure 39. Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older 142
- Measure 40. Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older 143
- Measure 41. Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older 144

Measures Category: Otitis 145

- Measure 91. Acute Otitis Externa (AOE): Topical Therapy 145
- Measure 93. Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use 145

Measures Category: Otological Evaluation 147

- Measure 261. Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness 147

Measures Category: Pacemaker and Implantable**Cardioverter-Defibrillator 148**

- Measure 348. HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate 148

- Measure 393. Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision 149

Measures Category: Pain Management 150

- Measure 131. Pain Assessment and Follow-up 150
- Measure 342. Pain Brought Under Control within 48 Hours 151

Measures Category: Pathology and Laboratory**Reports 152**

- Measure 249. Barrett's Esophagus 152
- Measure 250. Radical Prostatectomy Pathology Reporting 152
- Measure 251. Quantitative Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients 153
- Measure 265. Biopsy Follow-Up 154

Measures Category: Perioperative Treatments 155

- Measure 21. Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin 155
- Measure 22. Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures) 156
- Measure 23. Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) 157
- Measure 193. Perioperative Temperature Management 157
- Measure 399. Post-Procedural Optimal Medical Therapy Composite (Percutaneous Coronary Intervention) 158

Measures Category: Pregnancy 160

- Measure 254. Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain 160
- Measure 255. Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure 161
- Measure 335. Maternity Care: Elective Delivery or Early Induction Without Medical Indication at ≥ 37 and < 39 Weeks 161
- Measure 336. Maternity Care: Post-Partum Follow-up and Care Coordination 162

Measures Category: Preventive Care and**Screening 163**

- Measure 110. Preventive Care and Screening: Influenza Immunization 163
- Measure 111. Pneumonia Vaccination Status for Older Adults 164
- Measure 112. Breast Cancer Screening 164
- Measure 113. Colorectal Cancer Screening 165
- Measure 128. Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan 166
- Measure 173. Preventive Care and Screening: Unhealthy Alcohol Use—Screening 167

Measure 226. Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	167	Measures Category: Stroke	183
Measure 317. Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented	168	Measure 32. Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	183
Measure 320. Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients	169	Measure 33. Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	184
Measure 337. Tuberculosis Prevention for Psoriasis Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier	170	Measure 187. Stroke and Stroke Rehabilitation: Thrombolytic Therapy	184
Measure 343. Screening Colonoscopy Adenoma Detection Rate Measure	170	Measure 195. Radiology: Stenosis Measurement in Carotid Imaging Reports	185
Measure 394. Immunizations for Adolescents	171	Measures Category: Urinary Incontinence Measures	186
Measure 402. Tobacco Use and Help with Quitting Among Adolescents	171	Measure 48. Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	186
Measures Category: Radiology/Nuclear Medicine Services	173	Measure 50. Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	186
Measure 145. Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	173	Chapter 5: Measures Groups	189
Measure 146. Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Screening Mammograms	174	Measures Groups Specifications	191
Measure 147. Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	174	Acute Otitis Externa (AOE) Measures Group	191
Measure 225. Radiology: Reminder System for Screening Mammograms	175	Asthma Measures Group	192
Measure 262. Image Confirmation of Successful Excision of Image-Localized Breast Lesion	175	Cataracts Measures Group	192
Measure 322. Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients	176	Chronic Kidney Disease (CKD) Measures Group	193
Measure 323. Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)	176	Chronic Obstructive Pulmonary Disease (COPD) Measures Group	194
Measure 324. Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients	177	Coronary Artery Bypass Graft (CABG) Measures Group	194
Measures Category: Rehabilitation	178	Coronary Artery Disease (CAD) Measures Group	195
Measure 243. Cardiac Rehabilitation Patient Referral from an Outpatient Setting	178	Dementia Measures Group	196
Measures Category: Sinusitis	180	Diabetes Measures Group	197
Measure 331. Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Appropriate Use)	180	General Surgery Measures Group	198
Measure 332. Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)	181	Heart Failure (HF) Measures Group	199
Measure 333. Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)	181	Hepatitis C Measures Group	199
Measure 334. Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)	182	HIV/AIDS Measures Group	200
		Inflammatory Bowel Disease (IBD) Measures Group	201
		Oncology Measures Group	201
		Optimizing Patient Exposure to Ionizing Radiation Measures Group	202
		Parkinson's Disease Measures Group	203
		Preventive Care Measures Group	203
		Rheumatoid Arthritis (RA) Measures Group	204
		Sinusitis Measures Group	205
		Sleep Apnea Measures Group	206
		Total Knee Replacement Measures Group	206
		Chapter 6: Measure Worksheets	207
		Chapter 7: Condition Worksheets	395
		COPD Worksheet	396
		Adult Asthma Worksheet	397
		CAD Worksheet	398
		Heart Failure Worksheet	399
		Preventive Care Worksheet	400
		Ischemic Vascular Disease Worksheet	402
		Glossary	403

Measures Category: Hematology and Oncology Measures

Measure Number	Measure Title	Reporting Options					Reporting Frequency
		Claims-Based	Registry	Measures Groups	EHR-Based	GPRO/ACO	
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow		X				Once per the reporting period.
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy		X				Once per the reporting period.
69	Hematology: Multiple Myeloma: Treatment With Bisphosphonates		X				Once per the reporting period.
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry		X				Once per the reporting period.
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	X	X	X	X		Once per the reporting period.
72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients	X	X	X	X		Once per the reporting period.
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	X	X				At each pathological examination.
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	X	X				At each pathological examination.
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients		X		X		Once per treatment episode.
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients		X				Once per treatment episode.
143	Oncology: Medical and Radiation—Pain Intensity Quantified		X	X	X		At each visit.
144	Oncology: Medical and Radiation—Plan of Care for Pain		X	X			At each visit.
156	Oncology: Radiation Dose Limits to Normal Tissues	X	X				Once per the reporting period.
194	Oncology: Cancer Stage Documented		X				Once per the reporting period.
263	Preoperative Diagnosis of Breast Cancer	X	X				Each time an eligible patient undergoes a breast cancer surgery during the reporting period.
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer		X				Each time an eligible patient undergoes an SLN procedure during the reporting period.
395	Lung Cancer Reporting (Biopsy/Cytology Specimens)	X	X				Each time.
396	Lung Cancer Reporting (Resection Specimens)	X	X				Each time.

Measure 67. Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

Description:

This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of MDS or an acute leukemia who had baseline cytogenetic testing performed on bone marrow.

Associated Denominator Codes:

The ICD-9-CM code indicating acute leukemia not in remission (ICD-9-CM codes 204.00, 204.02, 205.00, 205.02, 206.00, 206.02, 207.00, 207.02, 207.20, 207.22, 208.00, 208.02, 238.72–238.75) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:

3155F Cytogenetic testing performed on bone marrow at time of diagnosis or prior to initiating treatment (HEM)

Associated Performance Modifiers:

1P Performance measure not performed, due to medical reasons

2P Performance measure not performed, due to patient reasons

3P Performance measure not performed, due to system reasons

8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:

- There are no allowable performance exclusions for this measure.
- Baseline cytogenetic testing is defined as testing performed at the time of diagnosis or prior to initiating treatment such as transfusion, growth factors, or antineoplastic therapy for that diagnosis.
- If the medical documentation references baseline bone marrow cytogenetic testing at the time of diagnosis or before the initiation of treatment, report 3155F.
- If the medical documentation does not reference baseline bone marrow cytogenetic testing at the time of diagnosis or prior to the initiation of therapy due to medical reasons that exclude the patient from the denominator, report 3155F with exclusion modifier 1P.
- If the medical documentation does not reference baseline bone marrow cytogenetic testing at the time of diagnosis or prior to the initiation of therapy due to patient reasons that exclude the patient from the denominator, report 3155F with exclusion modifier 2P.
- If the medical documentation does not reference baseline bone marrow cytogenetic testing at the time of diagnosis or prior to the initiation of therapy due to system reasons that exclude the

patient from the denominator, report 3155F with exclusion modifier 3P.

- If there is no documentation of baseline bone marrow cytogenetic testing in the medical documentation at the time of diagnosis or prior to initiating therapy and the reason is not specified, report 3155F with modifier 8P.
- This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure's denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data code 3155F (with modifier 1P, 2P, 3P, or 8P as applicable) does not have to be reported. However, these codes may be reported for registries that utilize claims data.

Measure 68. Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

Description:

This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of MDS who are receiving erythropoietin therapy with documentation of iron stores prior to initiating erythropoietin therapy.

Associated Denominator Codes:

The ICD-9-CM code indicating MDS (ICD-9-CM codes 238.72–238.75), the patient encounter code (CPT codes 99201–99205, 99212–99215) and Category II code 4090F indicating the patient is receiving erythropoietin therapy identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:

3160F Documentation of iron stores prior to initiating erythropoietin therapy (HEM)

Associated Performance Modifiers:

3P Performance measure not performed, due to system reasons

8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:

- There are no allowable performance exclusions for this measure.
- Documentation of iron stores requires one of two documents contained in the medical record: bone marrow examination including iron stain or serum iron measurement, including ferritin, serum iron, and TIBC.
- Erythropoietin therapy includes epoetin and darbepoetin for purposes of this measure.
- If the medical documentation references iron stores prior to the initiation of erythropoietin therapy, report 3160F.

- If the medical documentation does not reference iron stores prior to the initiation of erythropoietin therapy due to system reasons that exclude the patient from the denominator, report 3160F with exclusion modifier 3P.
- If there is no documentation of iron stores in the medical documentation prior to initiating erythropoietin therapy, and the reason is not specified, report 3160F with modifier 8P.
- This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure's denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data codes 3160F (with modifier 3P or 8P as applicable), 4090F, and 4095F do not have to be reported. However, these codes may be reported for registries that utilize claims data.

Measure 69. Hematology: Multiple Myeloma: Treatment With Bisphosphonates

Description:

This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of multiple myeloma, NOT in remission, who were prescribed or received bisphosphonate therapy within the 12-month reporting period.

Associated Denominator Codes:

The ICD-9-CM code indicating multiple myeloma (ICD-9-CM codes 203.00, 203.02) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:

4100F Bisphosphonate therapy, intravenous, ordered or received (HEM)

Associated Performance Modifiers:

1P Performance measure not performed, due to medical reasons

2P Performance measure not performed, due to patient reasons

8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:

- There are no allowable performance exclusions for this measure.
- Prescribed medication includes patients who are currently receiving medications that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter.
- Bisphosphonate therapy includes pamidronate and zoledronate for purposes of this measure.

- When intravenous bisphosphonate therapy is prescribed or received, report 4100F.
- When the bisphosphonate therapy is NOT prescribed or is NOT received by the patient for medical reasons, report 4100F with exclusion modifier 1P.
- When the bisphosphonate therapy is NOT prescribed or is NOT received by the patient for patient reasons, report 4100F with exclusion modifier 2P.
- When the therapy is NOT prescribed and medical record documentation does not indicate a reason, report 4100F with modifier 8P.
- This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure's denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data code 4100F (with modifier 1P, 2P, or 8P as applicable) does not have to be reported. However, it may be reported for registries that utilize claims data.

Measure 70. Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

Description:

This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of CLL who had baseline flow cytometry studies performed.

Associated Denominator Codes:

The ICD-9-CM code indicating a diagnosis with CLL not in remission (ICD-9-CM codes 204.10, 204.12) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:

3170F Flow cytometry studies performed at time of diagnosis or prior to initiating treatment (HEM)

Associated Performance Modifiers:

1P Performance Measure not performed, due to medical reasons

2P Performance measure not performed, due to patient reasons

3P Performance measure not performed, due to system reasons

8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:

- There are no allowable performance exclusions for this measure.

- CMS defines baseline flow cytometry studies to be testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include antineoplastic therapy.
- If the patient has baseline flow cytometry studies performed, report 3170F.
- If the patient was not prescribed or did not receive baseline flow cytometry studies performed because one of the exclusion criteria was documented, report 3170F with the appropriate exclusion modifier:
 - 1P Performance measure not performed, due to medical reasons
 - 2P Performance measure not performed, due to patient reasons
 - 3P Performance measure not performed, due to system reasons
- If the patient was not prescribed or did not undergo baseline flow cytometry studies and the reason is not specified, report 3170F with modifier 8P.
- This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure's denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data code 3170F (with modifier 1P, 2P, 3P, or 8P as applicable) does not have to be reported. However, it may be reported for registries that utilize claims data.

Measure 71. Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer

Description:

This quality measure identifies the percentage of female patients aged 18 years or older with a diagnosis of stage IC-IIIC, ER/PR positive breast cancer prescribed hormonal therapy, such as tamoxifen or aromatase inhibitor (AI), during the 12-month reporting period.

Associated Denominator Codes:

The ICD-9-CM code indicating a diagnosis of breast cancer (ICD-9-CM codes 174.0-174.6, 174.8, 174.9) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:

- 3315F Estrogen receptor (ER) and progesterone receptor (PR) Positive breast cancer (ONC)
- 3316F Estrogen receptor (ER) and progesterone receptor (PR) Negative breast cancer (ONC)
- 3370F AJCC Breast Cancer Stage 0, documented (ONC)
- 3372F AJCC Breast Cancer Stage I: T1 mic, T1a or T1b (tumor size ≤ 1cm), documented (ONC)

- 3374F AJCC Breast Cancer Stage I: T1c (tumor size > 1cm to 2cm), documented (ONC)
- 3376F AJCC Breast Cancer Stage II, documented (ONC)
- 3378F AJCC Breast Cancer Stage III, documented (ONC)
- 3380F AJCC Breast Cancer Stage IV, documented (ONC)
- 4179F Tamoxifen or aromatase inhibitor (AI) prescribed (ONC)

Associated Performance Modifiers:

- 1P Performance Measure not performed, due to medical reasons
- 2P Performance measure not performed, due to patient reasons
- 3P Performance measure not performed, due to system reasons
- 8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:

- There are no allowable performance exclusions for this measure.
 - Prescribed is defined by CMS as including the prescription given to the patient for tamoxifen or aromatase inhibitor (AI) at one or more visits in the 12-month reporting period OR according to a current medication list, the patient is already taking one of these drugs.
 - If tamoxifen or aromatase inhibitor is prescribed, report the code for tamoxifen or aromatase inhibitor (AI) prescribed (4179F), a code indicating the positive receptor (3315F), and the appropriate breast cancer staging code from below:
 - 3374F AJCC Breast Cancer Stage I: T1c (tumor size > 1cm to 2cm), documented
 - 3376F AJCC Breast Cancer Stage II, documented
 - 3378F AJCC Breast Cancer Stage III, documented
 - If the patient was not prescribed or did not receive tamoxifen or aromatase inhibitor at the time of the visit for medical, patient, or system reasons, report 4179F with the appropriate exclusion modifier:
 - 1P Performance measure not performed, due to medical reasons
 - 2P Performance measure not performed, due to patient reasons
 - 3P Performance measure not performed, due to system reasons
- AND the appropriate staging code from the list above, as well as the receptor code (3315F).
- If the patient is not eligible for this measure because the patient is estrogen (ER) and progesterone receptor (PR) negative, report 3316F.
 - If the patient is not eligible for this measure because the stage of cancer is not stage 1c through 111c breast cancer, report one of the following.
 - 3370F AJCC Breast Cancer Stage 0, documented
 - 3372F AJCC Breast Cancer Stage 1: T1 mic, T1a or T1b (tumor size ≤ 1 cm), documented
 - 3380F AJCC Breast Cancer Stage IV, documented

- If the patient was not eligible for this measure because the cancer stage or ER/PR is not documented, report one of the following:
 - 3316F-8P No documentation of estrogen receptor (ER) and progesterone receptor (PR) status
 - 3370F-8P No documentation of cancer stage
- If the patient was not prescribed or did not receive tamoxifen or aromatase inhibitor at the time of the visit and the reason was not specified, report 4179F with modifier 8P, the appropriate QDC to indicate the breast cancer stage (3374F, 3376F, or 3378F), and the ER/PR positive code (3315F).
- This measure is included in the Oncology Measures Group. See the Group Measures section for more information regarding the reporting of this measures group.
- This measure is reportable only through a registry and the EHR reporting options. When reporting via a registry, the patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure's denominator. The numerator options as described above are used to report the numerator of the measure. The quality-data codes described above do not have to be reported. However, these codes may be reported for registries that utilize claims data.

Measure 72. Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients

Description:

This quality measure identifies the percentage of patients, aged 18 to 80 years, with a diagnosis of AJCC stage III colon cancer who were referred, prescribed, or who previously received adjuvant chemotherapy during the reporting period.

Associated Denominator Codes:

The ICD-9-CM code indicating a diagnosis of colon cancer (ICD-9-CM codes 153.0-153.4, 153.6-153.9) and the patient encounter code (CPT codes 99201-99205 and 99212-99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:

- 3382F AJCC Colon Cancer Stage 0, documented (ONC)
- 3384F AJCC Colon Cancer Stage I, documented (ONC)
- 3386F AJCC Colon Cancer Stage II, documented (ONC)
- 3388F AJCC Colon Cancer Stage III, documented (ONC)
- 3390F AJCC Colon Cancer Stage IV, documented (ONC)
- G8927 Adjuvant chemotherapy referred, prescribed or previously received for AJCC Stage III colon cancer

G8928 Adjuvant chemotherapy not prescribed or previously received, reason given

G8929 Adjuvant chemotherapy not prescribed or previously received, reason not given

Associated Performance Modifiers:

8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:

- There are no allowable performance exclusions for this measure.
- CMS defines adjuvant chemotherapy using current NCCN guidelines. The following therapies are recommended:
 - 5-FU/LV/oxaliplatin (mFOLFOX6) as the standard of care (category 1)
 - bolus 5-FU/LV/oxaliplatin (FLOX, category 1)
 - capecitabine/oxaliplatin (CapeOx, category 1)
 - single agent capecitabine (category 2A) or 5-FU/LV (category 2A) in patients felt to be inappropriate for oxaliplatin therapy
- The definition of prescribed includes a prescription ordered for the patient for adjuvant chemotherapy at one or more visits in the 12-month period OR patient already receiving adjuvant chemotherapy as documented in the current medication list.
- If the patient was referred for, prescribed, or previously received neoadjuvant or adjuvant chemotherapy, report 3388F and G8927.
- If the patient was not referred, prescribed, or is not receiving chemotherapy for a documented reason, report 3388F and G8928.
- If the patient was not referred for, prescribed, or receiving chemotherapy and the reason is not given, report 3388F and G8929.
- If the patient is not eligible for this measure because the stage of cancer is not documented, report 3382F with modifier 8P.
- If the patient is not eligible for this measure because the patient is not stage III colon cancer, report one of the following:
 - 3382F AJCC Colon Cancer Stage 0, documented
 - 3384F AJCC Colon Cancer Stage I, documented
 - 3386F AJCC Colon Cancer Stage II, documented
 - 3390F AJCC Colon Cancer Stage IV, documented
- This measure is included in the Oncology Measures Group. See the Group Measures section for more information regarding the reporting of this measures group.
- This measure is reportable only through a registry and the EHR reporting options. When reporting via a registry, the patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure's denominator. The numerator options as described above are used to report the numerator of the measure. The quality-data codes described above do not have to be reported. However, these codes may be reported for registries that utilize claims data.